How we work

We break down the traditional silos across the life-science industry and share information to increase accountability and facilitate progress.

IFPMA serves as the secretariat of the AMR Industry Alliance with the responsibility of implementing the activities endorsed by the Board. The Board is the governing body of the AMR Industry Alliance. It is responsible for the planning and oversight of AMR Industry Alliance’s activities.

Thomas Cueni

IFPMA

Thomas B. Cueni is Director General of IFPMA since 1 February 2017. Prior to joining IFPMA he was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland. For many years Thomas Cueni has been involved in the work of the European Federation of Pharmaceutical Industries and Associations, EFPIA, where he most recently served as Vice-Chair of the European Markets Committee and association representative on the Board. He represented the industry on the EU High Level Pharmaceutical Forum, was Chairman of EFPIA’s Economic and Social Policy Committee and Chairman of the EFPIA Task Force on the EU Commission’s Pharmaceutical Sector Inquiry. Thomas Cueni also represented Interpharma, which he successfully transformed from the association of Swiss Rx companies to the association of pharmaceutical research companies in Switzerland, on the Council of IFPMA. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”, and he served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basel, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).

Chair

Koen Laenen

Medicines for Europe

Koen Laenen joined Medicines for Europe in November 2018 as Regulatory Affairs and Quality Manager. At Medicines for Europe Koen is responsible for all regulatory, quality and EHS projects concerning the generic pharmaceutical industry in Europe. Prior to Medicines for Europe, Koen was Business Unit Director at Ardena NV leading a team of CMC writers and Regulatory Affairs Officers from 2015 till 2018. Prior to that Koen was working for +10 years for Jubilant Pharmaceuticals NV as Head of Operations. In this function he was overlooking the performance and deliveries of the R&D projects, Site Transfers and Bio-Equivalence Studies to ensure that the planned deliverables were executed on time. And to manage the Regulatory Affairs and Quality Assurance departments in Europe, to timely obtain and maintain all market. Koen has a university degree in biotechnology and prior to starting in the pharmaceutical business he worked for several years as researcher in molecular neurobiology at university of Ghent.

Industry associations representatives

Brendan Barnes

EFPIA

Brendan Barnes is Director Data Protection and IP at the European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world. Brendan Barnes joined EFPIA in 2002 to work on the alignment of national laws in new member states during the enlargement of 2004. Subsequently, he has been involved in EFPIA’s work on multilateral trade and intellectual property issues, including the EU’s legislation on product diversion and compulsory licensing and on issues relating to access to medicines. More recently, he has been involved in the development of new business models in the areas of neglected disease and infection. He previously worked in the pharmaceutical industry for 11 years, in a range of roles including Finance, Strategic Planning and Public Affairs, among other things coordinating work on the Montreal Protocol phase-out of CFC’s. In the course of his career he has also worked in a number of other industries in a range of finance roles. He has degrees in Psychology and Business. A UK national, he is married with two children.

Industry associations representatives

Gareth Morgan

Shionogi

Gareth Morgan is Senior Vice President and Head of Global Portfolio Management for Shionogi. In addition to leading the Portfolio Management team, Gareth is responsible for providing strategic and policy direction related to anti-infective agents, and frequently represents Shionogi on anti-infective related government affairs and policy assignments, particularly those associated with the growing threat of antimicrobial resistance. Gareth has more than 25 years of experience with pharmaceutical and biotech companies, including BMS, Bayer, Genentech (now Roche) and Hoechst-Roussel (now Sanofi). He has led or provided functional and strategic oversight to development programs across multiple geographies and therapeutic areas.

Research-based pharmaceutical companies representatives

Bruce Altevogt

Pfizer

Bruce Altevogt is a Vice President and Head External Medical Engagement within Pfizer Inc.’s Hospital Business Unit, which includes managing the industry leading AMR surveillance program, Atlas. Prior to this role he was a Senior Director of Science Policy and Science Advocacy within Global Policy and International Public Affairs. In this role Dr. Altevogt was responsible for managing policy issues in support of Pfizer’s research & development enterprise, vaccines and was lead for anti-microbial resistance policy. Prior to joining Pfizer Inc. Dr. Altevogt served as a senior program officer on the Board on Health Sciences Policy at the Institute of Medicine, where he led policy initiatives related to basic and translational research, drug discovery and development, and preparedness for catastrophic events. Dr. Altevogt received a doctorate from Harvard University’s Program in Neuroscience and a B.A. from the University of Virginia, where he majored in Biology and minored in South Asian Studies. He is a published author of multiple scientific articles.

Research-based pharmaceutical companies representatives

Sébastien Gagnon-Messier

Merck KGaA

Sébastien Gagnon-Messier is Senior Director at Merck KGaA, Darmstadt Germany. He joined Merck in 2015 and is a member of the Global Government and Public Affairs for the company’s healthcare business. He is responsible for policy engagement on AMR and is a member of the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) AMR Working Group, in addition to his work with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Through its Global Health Institute, Merck is committed to addressing topics highlighted by the Alliance, in particular with regards to building local knowledge in developing countries about infection prevention and surveillance methods. To mark its 350th anniversary last year, Merck announced the creation of the Future Insight Prize. Awarded annually, the prize will honor and enable outstanding achievements in science & technology in the areas of health, nutrition and energy with a research grant of up to € 1 million sponsored by Merck. The awards for 2019 and 2020 will be given to projects on pandemic preparedness and multi-drug resistance, respectively.

Research-based pharmaceutical companies representatives

Paul Schaper

MSD

Paul Schaper, Executive Director, Global Public Policy, leads global policy efforts at MSD in Global Pharmaceuticals, which includes a broad range of therapeutic areas from diabetes to cardiovascular disease, neuroscience, reproductive health, and infectious disease, including hepatitis, HIV, and antibiotics/antifungals. From 2013 – 2017, he served as the Board Member for the Private Sector Constituency on board of the Global Fund for HIV, TB, and Malaria. He currently serves as the Private Sector Alternate Board Member. He earned his B.A. and master’s degrees in public health policy and business administration from Emory University and a master’s degree in clinical psychology from Georgia State University.

Research-based pharmaceutical companies representatives

Adrian Thomas

Johnson & Johnson

Adrian Thomas, M.D., is the Vice President, Global Programs Strategy & Evaluation with the Johnson & Johnson Global Public Health organization. Adrian has a special interest in the fields of public health, commercial and market access strategy, and pharmaceutical policy. He also held numerous roles in market access including Global Head Health Economics & Market Access Medical Devices. He was Global Head of Market Access for Janssen, the pharmaceutical companies of Johnson & Johnson, as well as roles in risk management and drug safety, including Global Head of Benefit Risk Manager and Chief Safety Office for Janssen. Prior to joining J&J, Adrian held roles in regional medical affairs, drug development and product management for Schering-Plough and Eli Lilly. He is a clinical pharmacologist and vascular physician with experience in clinical trials design and methodology. Adrian is a Fellow of the Royal Australasian College of Physicians and the College of Medical Administrator’s. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia. He is based in New Hope, Pennsylvania.

Research-based pharmaceutical companies representatives

James Anderson

GlaxoSmithKline

In his role as Head of Corporate Government Affairs, James leads engagement with the UK Government to deliver GSK’s strategic agenda, spanning R&D, Manufacturing, Commercial and Corporate aspects of GSK’s three businesses: pharmaceuticals, vaccines, and consumer. He seeks creative opportunities to partner with the Government and to mitigate risks. James is a member of the Life Science Strategy Board. James also leads global GSK advocacy on Antimicrobial Resistance (AMR). He has advised policy development on AMR at the WHO, UN, EU Commission, the O’Neill Review and National Governments. He is Vice Chair of the Industry IFPMA AMR Committee and regularly speaks on behalf of industry, building on his role in developing the Davos Declaration and 2016 UNGA Industry AMR Roadmap. In the UK, James Chairs the ABPI AMR network and the Government-Industry AMR taskforce.

Research-based pharmaceutical companies representatives

Lloyd Payne

Evotec

Lloyd Payne is Executive Vice President of Anti-infectives at Evotec, a multinational preclinical drug discovery organisation, and site head of the Manchester (UK) site where much of the company’s anti-infective discovery and translational biology is performed. As part of his role, Lloyd Payne is the antibacterial portfolio head, leads global anti-infective operations and sits on the executive committee that is responsible for Evotec’s global CRO business. Prior to Evotec, Lloyd Payne was the founding CEO of Euprotec Ltd, a leading biology CRO dedicated to the delivery of specialist biology services to companies involved in the discovery and development of new antimicrobial agents. Lloyd Payne led the company from foundation in 2008 through significant growth, collaborating with numerous companies worldwide, and to a successful sale and integration into Evotec. Prior to co-founding Euprotec, Lloyd Payne was a medicinal chemist and worked on a range of programs in the oncology, inflammation, and infectious disease therapeutic areas. He was Chief Scientific Officer of a UK-based biopharmaceutical company focused on the development of novel classes of drug for the treatment of life-threatening fungal infections. Earlier in his career, Lloyd Payne was a senior medicinal chemist and Group Leader at Millennium Pharmaceuticals (now Takeda), based in the UK and the US. Lloyd sits on the Novo REPAIR Impact Fund SSB and has a strong passion for building innovative drug discovery partnerships and collaborating with companies to develop new drugs to treat serious infections. Lloyd Payne holds a PhD in synthetic organic chemistry, has published research in peer-reviewed journals, presented at conferences, and is a co-inventor on multiple patents related to drug discovery technologies as well as novel agents for the treatment of cancer, inflammation, and infection.

Research-based pharmaceutical companies representatives

Giancarlo Francese

Teva Pharmaceuticals

Giancarlo Francese has several years’ experience in R&D Pharmaceutical Industry drug development in early, late, launch, and post-marketing stages. His focus and expertise is on Global Health programs in partnership with external Global Health key players. Within Novartis, he worked in collaboration with external organizations for the development and introduction of new Tropical Medicines with a special focus on Malaria innovative treatments for adult and pediatric populations. With his team, he pioneered and implemented innovative R&D approaches for cost saving expanding drug accessibility to all. Giancarlo now is a member of the Teva Pharmaceuticals Ltd Social Impact and Responsibility group. He is based in Basel Switzerland. In his role, he leads the newly created Teva Access program: a key tenet of Teva as social impact strategy. In his role, he works on strategic partnerships with Global Health stakeholders to establish shared value initiatives. This work is intended to increase medicine access effectively to address unmet medical needs in LMICs. Giancarlo holds an MSc in Chemistry from Pavia University in Italy and a PhD in Supramolecular Chemistry from Bern University in Switzerland.

Generics companies representatives

Harshika Sarbajna

Sandoz

Harshika Sarbajna recently assumed the role of Global Head of Anti-Infectives for Sandoz, a Novartis Division. In this role, she is responsible for ensuring sustainable growth of the antibiotics portfolio at Sandoz, the largest provider of generic antibiotics globally, working closely with markets and various functions within Sandoz. In this role, she is also spearheading Sandoz & Novartis wide AMR Stewardship program, bringing together stakeholders both inside and outside the organization. She previously served as the Global Head of Strategy and Operations of the Biosimilars business unit within Sandoz, and was part of the business leadership team. During Harshika’s tenure, she successfully led development and implementation of the commercial, portfolio and manufacturing strategy of the biosimilars business that delivered two successful biosimilar launches in Europe, and double-digit growth of in-market products across the globe. Prior to Sandoz, Harshika served as the Head of business strategy for the biosimilars business at Dr. Reddy’s Lab, and drove growth across the portfolio in key markets including US, Asia, Latin America and Russia. Before joining Dr. Reddy’s, she led various executive-level advisory engagements on business and growth strategy for large Corporates and PE funds as principal consultant with The Parthenon Group. Harshika began her career at Infosys, working with retail businesses across Europe and the US on their customer acquisition and retention plans.

Generics companies representatives

Deborah M. Autor

Mylan

Deb Autor, Esq., is Head of Strategic Global Quality and Regulatory Policy at Mylan, one of the largest generics and specialty pharmaceutical companies in the world. In this role, Deb represents Mylan’s diverse and complex operations to government officials globally and advises Mylan’s most senior leaders on how to navigate and influence the regulatory landscape. She also leads Mylan’s work on international trade policy, preventing antimicrobial resistance, and implementing global serialization. Previously, as Mylan’s Global Head of Quality, Deb managed thousands of personnel around the world, driving quality improvements across scores of manufacturing sites. Prior to joining Mylan, Deb served for 12 years at FDA, most recently as Deputy Commissioner for Global Regulatory Operations and Policy, where she supervised more than 4,000 employees in FDA’s Office of Regulatory Affairs and Office of International Programs in their efforts to confront the challenges of globalization and import safety.

Generics companies representatives

Alba Tiley

Centrient Pharmaceuticals

Alba leads the Sustainable Antibiotics program at Centrient Pharmaceuticals where she works on sustainability and health issues such as antimicrobial resistance and environment, access to life-saving antibiotics and appropriate use. She represents Centrient Pharmaceuticals in industry platforms and within multi-stakeholder initiatives. Internally, she drives sustainability throughout the organization by coordinating local sustainability champions and sharing the impact of the global effort across the company. Alba has a Master’s degree in Strategic Management from the Rotterdam School of Management.

Generics companies representatives

Thierry Bernard

QIAGEN

Thierry is Senior Vice President, Head of Molecular Diagnostics Business Area at QIAGEN. He joined QIAGEN in February 2015 to lead QIAGEN’s growing presence in Molecular Diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare. Thierry previously worked at bioMérieux where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to bioMérieux, Thierry served in management roles in multiple international environments. He is a member of the Boards of Directors of four privately held U.S. companies, First Light Biosciences, HepatoChem, Daktari Diagnostics – where he also served as CEO – and NeuMoDx, as well as a private French company, Huttopia SA. Thierry has earned degrees from Sciences Po (Paris), 4 Harvard Business School, London School of Economics, and the College of Europe, and he is a member of French Foreign Trade Advisors.

Diagnostics companies representatives

Isabelle Tongio

bioMérieux

Isabelle Tongio has been the Director of Public and Governmental Affairs at bioMérieux since January 2018. Prior to this, Isabelle was Advisor to the Chairman of bioMérieux from April 2015 onwards, after having started at bioMérieux in the 1990s in a managerial position. Isabelle is also the Vice-President of the French In Vitro Diagnostics Trade Association (SIDIV) and involved with a number of healthcare organizations – as a Public Affairs Committee member of MEDTECH Europe, and a member of the International Committee of ADVAMED. She is a member of the Executive Committee of the French industrial-governmental project “antibiotic resistance” under the umbrella of the French Strategic Healthcare Committee (CSF). Isabelle has a rich and transverse experience, complementary skills acquired throughout her career, and solid diplomas that are the foundation of her professional actions. She obtained her education at EM Lyon Business School.

Diagnostics companies representatives

Adam Zerda

Becton, Dickinson and Company (BD)

Adam Zerda is Director, Antimicrobial Resistance (AMR) Strategy and Development for BD. BD efforts to help combat AMR include a broad portfolio of solutions strategically positioned to play an active role in addressing this threat. In his role, Adam is responsible for developing and executing BD’s strategy for combatting the challenge of AMR globally by working to help build awareness of AMR, engage external stakeholders in policy and advocacy efforts around AMR, and develop training and process improvement programs, focusing specifically on infection prevention and antimicrobial stewardship. In leading BD’s AMR efforts, Adam is accountable for developing and implementing organization-wide, cross-functional alignment around this issue by working collaboratively with businesses, regions and functions. Prior to this role, Adam has held positions in business development, strategic innovation and research and development at BD. He joined the company in 2007. Prior to BD, Adam held roles in product development for GE Plastics. Adam has a Ph.D. in Polymer Science and Engineering (2002) from the University of Massachusetts in Amherst and a B.S. in Chemistry (1998) from TCU. He is based in North Carolina where he additionally sits on the board of North Carolina BIO.

Diagnostics companies representatives

Manos Perros

Entasis Therapeutics

Manos Perros, Ph.D., has served as chief executive officer, co-founder and director at Entasis Therapeutics since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc. A chemist by training, Dr. Perros conducted his Ph.D. work in Belgium, France and Germany, and was an associate in the Biophysics department at Yale from 1993 to 1995. Dr. Perros received the PhRMA Discoverer’s Award in 2010.

Biotechnology companies/SMEs representatives

Anand Anandkumar

Bugworks

Anand is co-founder and CEO of Bugworks, a leading pharma start-up, one of a handful of companies working on developing novel classes of antibiotics to tackle the global problem posed by multi-drug resistant bacterial superbugs. The company’s lead asset, which is in preclinical development, is a novel dual target inhibitor with excellent potency against the entire list of WHO critical, high and medium threat pathogens. The company has won many national and international innovation awards including the Best start-up in India (2015), Economic Times Top Innovator award (2017), first company outside North America and Europe to win the coveted CARB-X grant, and has been featured in the CB-InSights 2019 list of top 36 global start-ups. Bugworks has prominently featured on leading global platforms including the BBC, Wellcome Trust, UNCTAD, CDC and Forbes.

Anand was previously co-founder and Managing Director, Cellworks, a company specializing in personalized oncotherapy, using mathematical modelling frameworks. He is also the Co-founder of the India semiconductor association (IESA), Member of Executive committee of India Biotech association (ABLE), member of Eta-Kappa-Nu and Tau-Beta-Pi International Engineering honors societies, and most recently elected to the board of the AMR Industry Alliance.

Biotechnology companies/SMEs representatives

Greg Frank

Biotechnology Innovation Organization (BIO)

Greg Frank is Director of Infectious Disease Policy, where he is responsible for BIO’s antimicrobial resistance (AMR), vaccine regulatory, and vaccine reimbursement policy. His role includes leading a group of almost 50 BIO member companies to develop policy solutions that address AMR. Dr. Frank also serves on the expert advisory committees of the Access to Medicines Foundation AMR Benchmark and Duke-Margolis Center for Health Policy Antimicrobial Incentives & Payment Reform Project. Prior to joining BIO, Dr. Frank served as Program Officer for Science and Research policy at the Infectious Diseases Society of America (IDSA), where Dr. Frank led policy initiatives on the infectious disease physician scientist workforce, dual use research of concern, and improving the development and clinical integration of infectious disease diagnostics that can address AMR. Dr. Frank received his doctorate in immunology at the University of Pittsburgh and pursued his postdoctoral training at the Laboratory of Viral Diseases at the National Institute of Allergy & Infectious Diseases. He has published multiple scientific articles in the field of infectious disease.

Biotechnology companies/SMEs representatives

stay informed

Subscribe to receive our updates

  • I consent to the storage of my data according to the Privacy Policy